| Title : Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers - Schmidt_2024_Clin.Transl.Sci_17_e70033 |
| Author(s) : Schmidt WK , Cortes-Puch I , McReynolds CB , Croston GE , Hwang SH , Yang J , Pedersen TL , Wagner KM , Pham TT , Hunt T , Hammock BD |
| Ref : Clin Transl Sci , 17 :e70033 , 2024 |
| Abstract : |
| PubMedSearch : Schmidt_2024_Clin.Transl.Sci_17_e70033 |
| PubMedID: 39300734 |
| Title : Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative - Hammock_2021_J.Med.Chem__ |
| Author(s) : Hammock BD , McReynolds CB , Wagner K , Buckpitt A , Cortes-Puch I , Croston G , Lee KSS , Yang J , Schmidt WK , Hwang SH |
| Ref : Journal of Medicinal Chemistry , : , 2021 |
| Abstract : |
| PubMedSearch : Hammock_2021_J.Med.Chem__ |
| PubMedID: 33550801 |
| Title : Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis - McReynolds_2019_Front.Pharmacol_10_533 |
| Author(s) : McReynolds CB , Hwang SH , Yang J , Wan D , Wagner K , Morisseau C , Li D , Schmidt WK , Hammock BD |
| Ref : Front Pharmacol , 10 :533 , 2019 |
| Abstract : |
| PubMedSearch : McReynolds_2019_Front.Pharmacol_10_533 |
| PubMedID: 31214021 |
| Title : Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases - Wagner_2017_Pharmacol.Ther_180_62 |
| Author(s) : Wagner KM , McReynolds CB , Schmidt WK , Hammock BD |
| Ref : Pharmacol Ther , 180 :62 , 2017 |
| Abstract : |
| PubMedSearch : Wagner_2017_Pharmacol.Ther_180_62 |
| PubMedID: 28642117 |